To overview the recent literature on the use of MRI and musculoskeletal ultrasonography (MSUS) in rheumatoid arthritis.
INTRODUCTION
Modern imaging has come of age as a robust biomarker for rheumatoid arthritis. The American College of Rheumatology (ACR) Clinical Trials Task Force Subcommittee on Imaging has presented the extensive validation for MRI in randomized control trials [1] . Musculoskeletal ultrasonography (MSUS) has established its role in many rheumatology clinics and training curriculae [2] . High-resolution grey scale ultrasonography (GSUS) and power Doppler ultrasonography (PDUS) assist the diagnostic performance of 2010 ACR/EULAR classification criteria in early detection of rheumatoid arthritis [3] . In this review, we focus on recent publications on the utility of MRI and MSUS in rheumatoid arthritis diagnosis, pathogenesis, clinical trials, and routine clinical practice.
MRI AND DIAGNOSIS OF RHEUMATOID ARTHRITIS
A recent European League Against Rheumatism (EULAR) task force has highlighted the importance of MRI as a sensitive diagnostic tool in doubtful clinical scenarios, and a specific predictor of treatment response in rheumatoid arthritis [4] . Krabben et al. examined 179 patients with early arthritis, performing a 68 tender and 66 swollen joint count, followed by extremity 1.5T MRI of metacarpophalangeal joints (MCPJs), wrist and metatarsophalangeal (MTP) joints. Synovitis and tenosynovitis at MCP and wrist joints were independently associated with clinical swelling. MRI could detect inflammation in 54-64% of joints with no clinical swelling [5] .
Van Steenbergen et al. [6 & ] examined a cohort with clinically suspected arthralgia (CSA). MRI inflammation (combined osteitis, synovitis, and tenosynovitis score !3) was present in 44% of 93 patients; 35% of 29 patients with MRI inflammation who were followed up progressed to overt arthritis within 4 months. In an early arthritis cohort, Stomp et al. [7] noted numerically higher scores for synovitis, tenosynovitis, and osteitis in rheumatoid arthritis as compared with other arthropathies, although the MRI score in rheumatoid arthritis was not statistically different from other arthritides. Anticitrullinated peptide antibody (ACPA) positive patients showed significantly higher scores for osteitis.
That MRI findings alone are not diagnostic of rheumatoid arthritis is not surprising. Tamai et al. studied 166 patients with undifferentiated arthritis; patients fulfilling the 1987 ACR criteria for rheumatoid arthritis at 1 year or those who were on disease modifying antirheumatic drugs (DMARDs) within the first year of symptoms were the reference standard. Osteitis was the most useful feature with a positive predictive value of 84.9%, followed by bone erosion (81%) and synovitis (72%). A decision tree algorithm, which involved applying the 2010 criteria followed by MRI-detected osteitis identified rheumatoid arthritis better than the 2010 rheumatoid arthritis classification criteria alone [8] .
The importance of tenosynovitis in early rheumatoid arthritis is a recent emerging theme. Nieuwenhuis et al. performed MRI of the MCPs and wrist in 178 patients with early arthritis. Tenosynovitis was present in 65% of the total cohort and significantly higher in patients with rheumatoid arthritis than those without rheumatoid arthritis (75 vs. 59%; P ¼ 0.023). Flexor tenosynovitis at MCPJ5 and extensor tenosynovitis at MCPJ2, MCPJ4, and wrists showed greater levels of tenosynovitis in the patients with rheumatoid arthritis, independent of joint synovitis. There was no association of ACPA seropositivity with tenosynovitis [9] .
MRI AND PATHOGENESIS IN RHEUMATOID ARTHRITIS
Conflicting reports exist on the relationship between obesity and rheumatoid arthritis progression. Baker et al. examined data from two large clinical trials. Radiographic progression at 52 weeks was significantly lower in the obese/overweight category compared with those with low/normal weight (P ¼ 0.002). Osteitis scores were also significantly higher in patients with low/normal BMI [10] . The pathogenic implications of these findings are unknown.
Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) and T2 mapping are techniques used to detect cartilage proteoglycan loss before macroscopic morphological deformity [11] . Herz et al. [12 & ] applied dGEMRIC and T2 mapping to cartilage in finger joints and compared extent of synovitis, osteitis, and bone erosions with cartilage microstructure. Although bone erosions did not have any association, synovitis and osteitis were related to cartilage damage. Schleich et al. looked for possible association between severity of RAMRIS synovitis and cartilage composition, assessed by dGEMRIC of MCPJs in patients with rheumatoid arthritis. This study [13] also showed a significant association between cartilage loss and severity of synovitis.
Rowbotham et al. [14] reported the novel feature of interosseous tendons tenosynovitis (47.7% of 44 patients studied), seen more often adjacent to MCP joints with synovitis than those without (P < 0.001); it was also more common in those with flexor tenosynovitis compared with those without (P < 0.001). Siddle et al. [15] showed increased number of erosions on the proximal and plantar aspects of the MTP joints in rheumatoid arthritis, suggesting that erosions (in these locations) may be mechanically driven.
MRI AND RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE
The discrepancy between true imaging-detected inflammation and clinical findings means MRI might improve our clinical tools. Baker et al. developed modified common composite disease activity
KEY POINTS
MRI and ultrasonography are highly sensitive modalities and their use can improve diagnostic criteria for rheumatoid arthritis.
The concept of subclinical inflammation has been established by MRI and ultrasonography, and is evident from the earliest phases of rheumatoid arthritis to those with sustained clinical remission.
MRI studies of cartilage composition have confirmed a close relationship between synovitis to cartilage proteoglycan loss.
As evidence on the predictive validity of early MRI findings for radiographic progression and functional outcomes accumulates, MRI is increasingly being employed in outcome assessment in rheumatoid arthritis therapy trials.
Reduced ultrasonography joint scores are being developed and validated to improve feasibility of both diagnosis and monitoring in routine clinical care.
scores using MRI inflammation as the standard, and validated the scores in a second large cohort. The modified scores had better predictive value for radiographic progression than the existing activity measures [16] .
Developing biomarkers that will predict clinical response to a given therapy remains a holy grail for the field. MacIsaac et al. [17] in a randomized, controlled trial of infliximab with methotrexate versus placebo with methotrexate, demonstrated different patterns of pretreatment gene expression in whole blood from dynamic contrast enhanced MRI responders and nonresponders.
MRI AND CLINICAL TRIALS IN RHEUMATOID ARTHRITIS
Data from a randomized trial involving 256 methotrexate-naïve patients with rheumatoid arthritis, imaged with conventional radiographs and MRI at multiple time points, demonstrated that high baseline synovitis and osteitis, increase in RAMRIS erosion score at weeks 12 and 24, and poor response to therapy at week 24 were independent predictors of radiographic progression at 12 months [18] . In a separate analysis based on large randomized controlled trial (RCT) data, this group also reported requirements for substantial reduction of sample size and study duration if MRI is used as the primary end point in clinical trials (Fig. 1) [19 && ]. This study [19 && ] also demonstrated that early MRI progression of damage scores positively correlated with 2-year HAQ scores.
MRI has been used extensively as an outcome tool in assessing biologics. Peterfy et al. [20 & ] utilized MRI in a RCT in which bone erosion progression and cartilage loss (measured using a novel semiquantitative score) were reduced significantly in the rituximab (RTX) groups. In a phase II MRI substudy involving apremilast, there were no significant changes in the inflammation measures (synovitis and osteitis) at week 16 for two doses of apremilast (20 and 30 mg). However, around 80% of patients receiving apremilast did not show any worsening of erosions or joint space narrowing [21] . Ostergaard et al. used multiple MRI time points in 41 patients with established rheumatoid arthritis treated with certolizumab for 16 weeks, followed by a 24-week open-label extension. Significant reduction in synovitis and osteitis scores was observed at week 16. This study [22] provided information about the timing of early MRI endpoints for subsequent studies. MRI was also used to assess a treat-to-target strategy with methotrexate, intra-articular steroid and adalimumab/placebo in patients with early rheumatoid arthritis. Adding adalimumab had an additive effect in suppressing osteitis and tenosynovitis at 1 year [23] .
More recently, another study explored the effects of tofacitinib alone or in combination with MTX versus MTX alone on a range of MRI endpoints including a novel automated method quantifying RAMRIS components (using active appearance modelling, called RAMRIQ) and compared this with RAMRIS and dynamic quantitative MRI. RAMRIQ was found to be more responsive in measuring outcomes, with significant differences in favor of both tofacitinib groups [24] .
NEW MRI SCORING SYSTEMS
Forefoot bursae (FFB) are associated with rheumatoid arthritis disease activity and predict foot disability. Cherry et al. [25] devised a novel MRIbased score for evaluation of FFBs in patients with rheumatoid arthritis, which was shown to have moderate to substantial reliability. Axelsen et al. investigated the ability of whole body MRI (WBMRI) in rheumatoid arthritis to detect inflammation and structural damage. Synovitis and osteitis by WBMRI were noted more frequently than clinical findings. WBMRI also determined (infrequent) enthesitis in patients with rheumatoid arthritis. This technology may underpin feasible systems to assess 'total body' inflammation and MRI 'joint counts' [26] .
MRI IN DETERMINING REMISSION
Ranganath et al. in a substudy to the Treatment of Early Aggressive Rheumatoid arthritis (TEAR) trial, assessed MRI findings across different clinical remission criteria in a seropositive early rheumatoid arthritis cohort over 2 years. Although total MRI inflammatory scores were lower during clinical remission, none of the patients had a score of zero for any variable at the end of the study [27] , supporting previous evidence on persistent subclinical disease in clinically apparent remission.
MUSCULOSKELETAL ULTRASONOGRAPHY AND DIAGNOSIS OF RHEUMATOID ARTHRITIS
A phase of preclinical rheumatoid arthritis, with rising titres of ACPA is now well recognized up to 2 years prior to disease onset [28] . A UK group studied 100 consecutive patients with new nonspecific musculoskeletal symptoms and positive ACPA. Half the patients progressed to inflammatory arthritis, mostly within the first 12 months. They devised a model for progression to inflammatory arthritis with three of four variables (tenderness of hand or foot joints, early morning stiffness !30 min, high-positive autoantibodies, and positive PDUS) strongly associated with inflammatory arthritis outcome [29 && ]. There is scarcity of data on the specificity of erosions in rheumatoid arthritis diagnosis. Zayat et al. examined the incident rate ratios of joints with erosions in patients with rheumatoid arthritis, psoriatic arthritis, gout, and osteoarthritis: they were 2.50, 2.28, and 5.41, respectively. Presence of any joint with extensive erosive damage was specific for rheumatoid arthritis (89.2%) but not very sensitive (50%). Large erosions in the second and fifth MCPJ, fifth MTPJ, and distal ulna were highly specific (97.9%) but moderately sensitive (41.4%) for rheumatoid arthritis. The authors observed a diameter of !1.5 mm achieved the best trade-off between sensitivity and specificity for rheumatoid arthritis diagnosis [30] .
Minowa et al. studied 122 treatment-naïve undifferentiated patients with arthritis with MSUS and laboratory findings. MSUS evaluation was performed on proximal interphalangeal (PIP), MCPJs, and both wrists. During follow up, the diagnosis of rheumatoid arthritis was defined by the attending physician. In seropositive rheumatoid arthritis, the ACR/EULAR classification criteria (OR ¼ 15.53) and power Doppler at least 2 for at least 1 joint (OR ¼ 10.48) were the contributing factors, whereas only the latter variable contributed (OR ¼ 20.00) in sero-negative patients [31] .
MUSCULOSKELETAL ULTRASONOGRAPHY AND PATHOGENESIS IN RHEUMATOID ARTHRITIS
An Italian group has reported a strong correlation of GSUS and PDUS in 12 treatment-naïve early patients with rheumatoid arthritis with pro-angiogenic and lymphangiogenic gene expression profiles [32] . Another study on 177 patients with rheumatoid arthritis compared synovial histology (from 215 joints undergoing synovectomy and reconstructive surgery) with MSUS. Power Doppler signal grade reflected the histological scores in both large and small joints and also correlated well with DAS28, Creactive protein, and matrix metalloproteinase-3 [33] .
Alsuwaidi et al. performed high-resolution MSUS, including PDUS of ankle joints in 80 patients of rheumatoid arthritis with a mean DAS28 score of 5.0. Tibiotalar and talonavicular joints were observed to have the most synovitis in both symptomatic and asymptomatic patients. Half the asymptomatic joints showed signs of synovitis on scanning. However, PDUS activity was seen predominantly in symptomatic patients [34 
MUSCULOSKELETAL ULTRASONOGRAPHY AND RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE
The randomized targeting synovitis in early rheumatoid arthritis study investigated the utility of MSUS in improving the accuracy of disease activity assessments. MSUS identified persistent disease activity in a quarter of patients with low disease activity or clinical remission and led to modified therapeutic decisions in 29% of assessments. On the flip side, in 67% assessments, MSUS did not identify active disease in the moderate disease activity but minimal clinical synovitis group, preventing treatment escalation [36] . The optimal time point for repeat rituximab (RTX) in rheumatoid arthritis has not been clearly defined. Reiche et al. [37] evaluated MSUS changes in 20 patients with longstanding rheumatoid arthritis with moderate to high disease activity (mean DAS28 5.3 AE 1.0) on RTX, and compared the findings with clinical and laboratory data. A seven-joint (wrist, MCP/PIP joints 2 and 3, and MTP joints 2/5) grey scale and PDUS score (US7) was calculated for synovitis, tenosynovitis, and GSUS for erosions [38] . PDUS was a better score to decide on RTX re-therapy as it detected onset of disease activity before worsening of clinical symptoms.
Another recent theme in imaging has been its ability to enable tapering or withdrawal of biologics. Naredo et al. investigated the predictive value of PDUS detected synovitis for predicting failed biologic therapy at 6 and 12 months in 77 patients with rheumatoid arthritis in sustained clinical remission. Within 12 months, 14 (30.4%) patients on subcutaneous biologics and 21 (67.7%) patients on intravenous biologics developed tapering failure. Baseline DAS28 and high global score of PDUS synovitis were the independent predictors of biologic therapy failure [39 & ].
MUSCULOSKELETAL ULTRASONOGRAPHY AND CLINICAL TRIALS IN RHEUMATOID ARTHRITIS
The short-term PDUS response to anti-TNFa therapy in six target joints (second MCP, wrist and knee bilaterally) was monitored in 68 patients with rheumatoid arthritis. There was significant decrease in the joint score at all articular sites, and a moderate significant positive correlation between the global PDUS score and change in DAS28 at 3 months [40] . The APPRAISE study assessed the capability of a composite PDUS score (improvement in the global OMERACT-EULAR synovitis score of bilateral MCP 2-5) to measure early effect and time to response to abatacept in 104 biologic-naïve patients with rheumatoid arthritis who were MTX inadequate responders. Both composite PDUS score and PD signal showed statistically significant reductions in individual joint synovitis by week 1. There was a continuous improvement in the global score (MCP 2-5) and each of the component scores until 24 weeks. The authors proposed a novel nine-paired joint set (shoulder, elbow, wrist, MCP 1, MCP4, PIP joint-PIP 2, knee, MTP 3, and MTP 5) which worked as well as a 22-paired joint set for disease activity monitoring [41 && ].
NEW MUSCULOSKELETAL ULTRASONOGRAPHY SCORING SYSTEMS
There remains no standard guideline on the number of joints to be used for monitoring rheumatoid Fukae et al. studied patients with rheumatoid arthritis with sustained clinical low disease activity using PDUS to measure quantitative synovial vascularity. MCP and PIP joints with positive synovial vascularity had significantly higher changes of TSS (P < 0.0001) and joint space narrowing score (P < 0.0001) compared with those with negative synovial vascularity [48] .
CONCLUSION
MRI and ultrasonography are finding increasing utility in rheumatoid arthritis both in research, where imaging will mean smaller and shorter duration clinical trials, and in clinical practice. Future research to optimize the role of MRI and ultrasonography in management of rheumatoid arthritis must address recommendations for specific joints to be assessed for both diagnosis and monitoring, and support the role of imaging in cost-effective clinical management algorithms. Improving technology and quantification will continue to evolve the usefulness of modern imaging. 
